Abigail Brooks, MA

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.

Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.

Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.

Lacy reviews key considerations for the diagnostic evaluation and treatment of abdominal bloating and distension based on his session at DDW.

Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.

Singh explains a potential new approach to the low FODMAP diet based on findings from research he presented at DDW suggesting a simplified step-up method.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.

Joly explains the burden of parenteral support and the significance of new STARS data showcasing apraglutide’s potential in SBS-IF.

Alkhouri explains survodutide’s mechanism of action as a glucagon/GLP-1 receptor dual agonist and reviews key findings about its use in MASH from the interim analysis.

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.

New STARS data were presented in a late-breaking abstract at DDW and build upon positive topline results for clinical responder rates and reductions in parenteral support.

Feuerstadt breaks down findings from an ad hoc analysis of PUNCH CD3 and what the results suggest about the use of live-jslm (Rebyota) in patients taking concomitant medications.

Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.

Damas explains key findings from her pilot study exploring intervals of a low-calorie plant-based diet as adjunctive therapy to medication in patients with ulcerative colitis.

Rezaie describes recent trends in GLP-1RA prescription patterns from his population-based research presented at DDW, highlighting increases in off-label use.

Dolinger reviews findings from his research presented at DDW about the use of intestinal ultrasound response for predicting endoscopic outcomes in children with UC.

Damas explains what inspired her research about the impact of a low-calorie plant-based diet on clinical response to medication in patients with ulcerative colitis.

Findings were presented at DDW and highlight the feasibility of breath analysis for microbiome metabolic characterization in the digestive system.

Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.